1,116 results on '"Haustermans K"'
Search Results
2. Patients’ needs in proton therapy: A survey among ten European facilities
3. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
4. Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study
5. Letter to the editor regarding “External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts” by M. Berbée et al.
6. Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648
7. Oesofaguscarcinoom
8. When Should IGRT Be Done?
9. Which Margin Should Be Added to the GTV?
10. Oesofaguscarcinoom
11. MO-0558 Patients’ needs in Proton Therapy: a survey among 10 European Facilities
12. PD-0889 Functional lung dose and postoperative lung complications in esophageal cancer trimodality therapy
13. PD-0077 Electronic Patient Reported Outcomes in follow-up after palliative radiotherapy: a feasibility study
14. PO-1955 PBS proton arc therapy may improve focal boosting compared to VMAT for localised prostate SBRT
15. OC-0922 Once or twice a week, What's best?: Joint acute toxicity analysis of the phase II hypo-FLAME trials
16. PO-2087 NTCP modelling with dosiomics features for postoperative complications in oesophageal cancer
17. PD-0078 Electronic Patient Reported Outcomes in follow-up after PRT: a national survey study
18. ‘Scan-(pre)Plan-Treat’ workflow for bone metastases using the Ethos™ therapy system: a single center in silico experience.
19. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona
20. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
21. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
22. Radiation Therapy in Esophageal/Gastroesophageal Cancer
23. Is semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting in the phase II hypo-FLAME 2.0 trial associated with acceptable acute toxicity?
24. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
25. Reply to the Letter to the Editor 'Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten' (in regard to "Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up") by Huguet et al
26. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
27. SP-0917 Patterns of failure in the phase III randomized controlled FLAME trial for localized prostate cancer
28. SP-0023 Technical developments in the radiation treatment of oesophageal cancer
29. OC-0259 Focal boosting in prostate cancer: risk modelling for individualized therapy
30. Esophageal Tumors
31. Etablierung einer pan-europäischen Plattform zur Untersuchung von Gesundheitsfolgen medizinischer Strahlung für Krebspatienten im Kindes- und Jugendalter : Das EU- Projekt 'HARMONIC'
32. Personalised radiation therapy taking both the tumour and patient into consideration
33. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
34. Development of clinical trial protocols involving advanced radiation therapy techniques: The European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach
35. FISHING FOR THE FLASH EFFECT: DEFINING THE CRITICAL PARAMETERS TO OBSERVE THE FLASH EFFECT WITH PROTONS IN A ZEBRAFISH EMBRYO MODEL
36. Predicting patient-reported symptom clusters in prostate cancer patients: A machine learning approach
37. The Feasibility of Quality Assurance in the TOPGEAR International Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy for Gastric Cancer (An Intergroup Trial of the AGITG/TROG/EORTC/CCTG)
38. Metastasis-Directed Therapy for Oligoprogressive Castration-Resistant Prostate Cancer ― Preliminary Results of the Prospective, Single-Arm MEDCARE Trial
39. Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME? Reply
40. Proton and photon treatment planning comparison for oesophageal cancer between six European centres
41. Current practice for selection of adult patients for proton therapy across Europe
42. Cytokeratin 14, 18, and 19 Expression in Normal Epithelium and in Squamous Cancer of the Esophagus
43. Cell Kinetics and Epidermal Growth Factor Receptor Expression: Useful Guides in Esophageal Cancer?
44. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
45. PH-0328 Current practice for selection of adult patients for proton therapy across Europe
46. PD-0881 Deep learning dose prediction as a tool to evaluate treatment complications based on NTCP models
47. OC-0511 Urethra and bladder dose-effect relations for genitourinary toxicity after EBRT for prostate cancer
48. OC-0631 Proton and photon treatment planning comparison for oesophageal cancer between six European centres
49. PO-1437 Endocrine Late- Effects after Childhood and Adolescent Cancer - The Pan-European Registry HARMONIC
50. PD-0818 Dose prediction with deep learning: the effect of data quality and quantity in the model’s accuracy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.